Oncotarget: a Modern Scholarly Journal that Instantly Relays Research Findings

Oncotarget is a medical journal that publishes articles on topics, such as aging, oncology, immunology, and pathology. Dr. Mikhail Blagosklonny established this journal in 2010. Oncotarget is an open access medical journal that is published by Impact Journals on a weekly basis.

About Oncotarget

Dr. Mikhail Blagosklonny is a researcher at the Roswell Park Cancer Institute. He is experienced in the field of research, and he has authored numerous articles. His vast background in cancer research, and he has worked as an editor for various journals. Under his management, Oncotarget has received recognition as one of the platforms that relay research findings on time. As the senior editor of Oncotarget, Dr. Mikhail Blagosklonny ensures that authors provide sufficient references to their papers.Oncotarget was initially formed with the aim of publishing cancer reports, but it has since evolved such that it accommodates other topics. Some of the themes include endocrinology, cell biology, and neurology.

Oncotarget is also edited by Andrei V. Gudkov, who is also the founder of this journal. This scientist is involved in handling matters pertaining editing and management of the Oncotaget. He also supervises other junior editors of the journal. Aside from articles, Oncotarget also publishes book chapters and newsletters. Oncotarget’s target audience is mainly scholars and individuals in the field of cancer research. Oncotarget is indexed in the Index Medicus. MEDLINE/Pubmed, Scopus, Science Citation Index Expanded, and BIOSIS Previews. Oncotarget’s mission is mainly to:

  • Make known extraordinary scientific discoveries.
  • Impact research through insightful review
  • Link the different fields of medical sciences
  • Encourage the use of clinical sciences to fight life threatening diseases.
  • Merge various biomedical fields

Oncotarget’s associations

Oncotarget works with other associate professors from numerous institutions, including the California Institute of Technology, The Scripps Research Institute, Harvard University, the Institute for Advanced Studies, and John Hopkins University. Oncotarget also works with prominent researchers, such as Arnold Levine, Alexander Vrshavsky, Peter Vogt, and Gregg Semenza. Currently, Oncotarget is doing well, and it has accumulated a higher impact factor in the last couple years. Oncotarget is also listed among the fastest growing open access journals in the United States.

Groupon Founder Eric Lefkofksy’s New Mission: Creating Data-Driven Cancer Treatment

Eric Lefkofksy might be known for creating Groupon, the online backbone of the best local deals. However, according to Jim Dalke’s article in ChicagoInno titled “Eric Lefkofsky’s Self-Funded Mission to Cure Cancer Through Data”, the serial entrepreneur is about to shake up medical industry.

Mr. Lefkofsky created company after an incredibly confusing and disheartening experience. His wife was diagnosed with cancer. As they went from doctor to doctor, it became clear that the data necessary for an informed decision simply wasn’t available. The treatment did not seem personalized Lefkofksy decided a change was necessary.

Mr. Lefkofsky created Tempus as a solution to this issue. By making a library consisting of previous cancer patient’s molecular compositions and an operating system that interprets it, doctors will be able to create a personalized treatment plan for their current patients. The patients have their genomes sequenced in the lab and it is then lined up with the molecular information of other cancer patients. At that point, Tempus creates a report for the doctors and provides access to the operating system to create a precise treatment plan.

Though he has great hopes for Tempus, starting a new company was not at the top of his to-do list. At this point in his career, he was not looking for all the pressure and stress that is inherent in building a successful startup. However, he has invested much of his own fortune to keep Tempus self-funded, which allows it to outpace competitors who are reliant on outside funding.

He hopes that Tempus will be one of the most successful of his businesses because of the possible impact on people’s lives. He claims that the technology could be “the most disruptive model I’ve ever seen.” Though it may take years to measure the success of the treatment options based on the data, it has the potential to save lives.

The company established partnerships with some of the healthcare industry’s biggest hitters such as the University of Chicago, the Mayo Clinic, the University of Michigan, and Northwestern University.

Eric Lefkosky has been a successful entrepreneur since 2006. He has co-founded companies in a variety of different industries like predictive analytics, marketing, venture capital, and local commerce.

He is also dedicated to a variety of philanthropic causes. He co-founded the Lefkofksy Foundation with his wife to support education, science, and more than 50 other organizations. He is also a part of The Giving Pledge.